Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq plus Avastin demonstrated a statistically significant...
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), released preclinical data from the company’s portfolio of KIF18A inhibitors at...
A landmark paper published in The Lancet Neurology journal by leaders of the Parkinson's Progression Markers Initiative (PPMI), the gold-standard Parkinson's biomarker study sponsored by The...
M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomic data to accelerate medical product discovery, announced it is rebranding, changing the company's...
